Association of reduced total iron binding capacity and fungal infections in leukemic granulocytopenic patients

Judith Karp, W. G. Merz

Research output: Contribution to journalArticle

Abstract

Serum total iron-binding capacity (TIBC) was measured serially on 70 patients with acute leukemia throughout the period of chemotherapy-induced granulocytopenia. Fungal infections were documented in 13 of these patients (18.6%), while 41 patients (58.6%) had clinically suspected fungal infections and 16 (22.9%) had no evidence of fungal infections during the granulocytopenia. Documented fungal infection occurred in patients with the greatest reduction in TIBC (P <.015). Early reduction in TIBC also correlated with a greater risk for occurrence of fungal infection, and the earliest institution of amphotericin B (Amp-B) (P <.004). Effective antifungal therapy was further associated with a return of TIBC levels toward normal. These data demonstrate that altered iron metabolism during granulocytopenia is associated with the development of fungal infections in compromised patients. Serial monitoring of TIBC, along with other clinical and mycologic findings, may prove useful in developing strategies for predicting patients at risk for developing a fungal infection and directing the appropriate use of empiric therapy by Amp-B.

Original languageEnglish (US)
Pages (from-to)216-220
Number of pages5
JournalJournal of Clinical Oncology
Volume4
Issue number2
StatePublished - 1986

Fingerprint

Mycoses
Iron
Agranulocytosis
Amphotericin B
Leukemia
Drug Therapy
Therapeutics
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Association of reduced total iron binding capacity and fungal infections in leukemic granulocytopenic patients. / Karp, Judith; Merz, W. G.

In: Journal of Clinical Oncology, Vol. 4, No. 2, 1986, p. 216-220.

Research output: Contribution to journalArticle

@article{991c4c00894c49f2b4a59b01dc2679dd,
title = "Association of reduced total iron binding capacity and fungal infections in leukemic granulocytopenic patients",
abstract = "Serum total iron-binding capacity (TIBC) was measured serially on 70 patients with acute leukemia throughout the period of chemotherapy-induced granulocytopenia. Fungal infections were documented in 13 of these patients (18.6{\%}), while 41 patients (58.6{\%}) had clinically suspected fungal infections and 16 (22.9{\%}) had no evidence of fungal infections during the granulocytopenia. Documented fungal infection occurred in patients with the greatest reduction in TIBC (P <.015). Early reduction in TIBC also correlated with a greater risk for occurrence of fungal infection, and the earliest institution of amphotericin B (Amp-B) (P <.004). Effective antifungal therapy was further associated with a return of TIBC levels toward normal. These data demonstrate that altered iron metabolism during granulocytopenia is associated with the development of fungal infections in compromised patients. Serial monitoring of TIBC, along with other clinical and mycologic findings, may prove useful in developing strategies for predicting patients at risk for developing a fungal infection and directing the appropriate use of empiric therapy by Amp-B.",
author = "Judith Karp and Merz, {W. G.}",
year = "1986",
language = "English (US)",
volume = "4",
pages = "216--220",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Association of reduced total iron binding capacity and fungal infections in leukemic granulocytopenic patients

AU - Karp, Judith

AU - Merz, W. G.

PY - 1986

Y1 - 1986

N2 - Serum total iron-binding capacity (TIBC) was measured serially on 70 patients with acute leukemia throughout the period of chemotherapy-induced granulocytopenia. Fungal infections were documented in 13 of these patients (18.6%), while 41 patients (58.6%) had clinically suspected fungal infections and 16 (22.9%) had no evidence of fungal infections during the granulocytopenia. Documented fungal infection occurred in patients with the greatest reduction in TIBC (P <.015). Early reduction in TIBC also correlated with a greater risk for occurrence of fungal infection, and the earliest institution of amphotericin B (Amp-B) (P <.004). Effective antifungal therapy was further associated with a return of TIBC levels toward normal. These data demonstrate that altered iron metabolism during granulocytopenia is associated with the development of fungal infections in compromised patients. Serial monitoring of TIBC, along with other clinical and mycologic findings, may prove useful in developing strategies for predicting patients at risk for developing a fungal infection and directing the appropriate use of empiric therapy by Amp-B.

AB - Serum total iron-binding capacity (TIBC) was measured serially on 70 patients with acute leukemia throughout the period of chemotherapy-induced granulocytopenia. Fungal infections were documented in 13 of these patients (18.6%), while 41 patients (58.6%) had clinically suspected fungal infections and 16 (22.9%) had no evidence of fungal infections during the granulocytopenia. Documented fungal infection occurred in patients with the greatest reduction in TIBC (P <.015). Early reduction in TIBC also correlated with a greater risk for occurrence of fungal infection, and the earliest institution of amphotericin B (Amp-B) (P <.004). Effective antifungal therapy was further associated with a return of TIBC levels toward normal. These data demonstrate that altered iron metabolism during granulocytopenia is associated with the development of fungal infections in compromised patients. Serial monitoring of TIBC, along with other clinical and mycologic findings, may prove useful in developing strategies for predicting patients at risk for developing a fungal infection and directing the appropriate use of empiric therapy by Amp-B.

UR - http://www.scopus.com/inward/record.url?scp=0022580483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022580483&partnerID=8YFLogxK

M3 - Article

C2 - 3944605

AN - SCOPUS:0022580483

VL - 4

SP - 216

EP - 220

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -